Search clinical trials for: HIV-1 Peptide Vaccine, Microparticulate Monovalent

Total 239 results

National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
United Biomedical

Completed

A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

HIV Infections

United States
United Biomedical

Completed

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Lederle-Praxis Biologicals

Completed

A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

HIV Infections

United States
National Liver Institute, Egypt

Unknown

Safety and Efficacy Study of CENV3 Vaccine to Protect Against HCV Infection (CENV3)

Vaccine Overdose of Undetermined Intent

Egypt
PATH
Bill and Melinda Gates Foundation; Centers for Disease Control and Prevention; The Emmes Company, LLC and other collaborators

Completed

Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines

Poliomyelitis

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Allogeneic Hematopoietic Stem Cell Transplant Recipient

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Evandro Chagas National Institute of Infectious... and other collaborators

Active, not recruiting

Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial (OPTIMO)

HIV Infection

Peru, Brazil, Haiti
National Cancer Institute (NCI)

Active, not recruiting

Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants

Human Papillomavirus-Related Carcinoma

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of California, Los Angeles; Merck... and other collaborators

Active, not recruiting

HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV (COVENANT)

HIV Infection | AIDS-Related Human Papillomavirus Infection | High Grade Cervical Squamous Intraepithelial Neoplasia

Uganda, Kenya, Zimbabwe, South Africa, Malawi
Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

HIV Infections | HIV-1
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)

HIV Infections

United States
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Active, not recruiting

Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Cervical Cancer | Cervical Intraepithelial Neoplasia | Condylomata Acuminata

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

High Grade Anal Canal Intraepithelial Neoplasia | High Grade Vulvar Squamous Intraepithelial Lesion

United States
National Cancer Institute (NCI)

Completed

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
Barbara Ensoli, MD
Novartis Vaccines

Terminated

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

HIV Infection

Italy
London School of Hygiene and Tropical Medicine
National Cancer Institute (NCI); Karolinska Institutet; Institut Català d'Oncologia and other collaborators

Active, not recruiting

A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls (DoRIS)

Human Papilloma Virus

Tanzania
M.D. Anderson Cancer Center
The Vaccine Company

Terminated

PR1 Vaccination in Myelodysplastic Syndrome (MDS)

Leukemia | Myelodysplastic Syndrome

United States
PATH
Bill and Melinda Gates Foundation; Centers for Disease Control and Prevention; PT Bio Farma and other collaborators

Recruiting

Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh

Poliomyelitis

Bangladesh
Aga Khan University
World Health Organization

Completed

Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3 (SIAD)

Polio

Pakistan
National Cancer Institute (NCI)

Active, not recruiting

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

Human Papillomavirus Infection

United States
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
Jun Zhang
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Active, not recruiting

Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine

Condylomata Acuminata
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML)

United States
University of British Columbia

Recruiting

A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV (NOVA-HIV)

Human Immunodeficiency Virus | HPV | Human Papilloma Virus

Canada
Beijing Health Guard Biotechnology, Inc
University of Muhammadiyah Malang Hospital; Dr. M Djamil Hospital, Padang

Active, not recruiting

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Human Papillomavirus Infection

Indonesia
International AIDS Vaccine Initiative
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

HIV Infections

Kenya, Zambia, Uganda
Hadassah Medical Organization
Vaxil Therapeutics Ltd.

Withdrawn

A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

Multiple Myeloma | Tumors

Israel
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects

HIV Infections

United States
Sanofi Pasteur, a Sanofi Company
GlaxoSmithKline

Completed

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)

COVID-19

Honduras, United States, Australia, France, New Zealand, Spain, United Kingdom
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
National Institute of Allergy and Infectious Diseases...

Completed

Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Unknown

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults

HIV Infections

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Beijing Health Guard Biotechnology, Inc
National Institutes for Food and Drug Control, China; Jiangsu Province Centers... and other collaborators

Completed

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Human Papillomavirus Infection

China
National Cancer Institute (NCI)

Not yet recruiting

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

Human Papillomavirus-Related Carcinoma

United States, Austria
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH)

Completed

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

Melanoma (Skin)

United States
Miquel Angel Pavon Ribas
Catalan Institute of Health; Hospital del Mar

Recruiting

A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV) (RIFT-HPV)

Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) | Human Papillomavirus (HPV) Infections | High-risk HPV | HPV-16/ 18

Spain
National Cancer Institute (NCI)

Completed

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

Cervical Cancer | High-grade Squamous Intraepithelial Lesion | Atypical Squamous Cells of Undetermined Significance | Low-grade Squamous Intraepithelial Lesion

United States
Novartis Vaccines

Completed

Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children

Haemophilus Influenzae Type b (Hib) Infection

China
National Institute of Allergy and Infectious Diseases...

Completed

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

HIV Infections

United States, Puerto Rico
Statens Serum Institut
Rigshospitalet, Denmark; Hvidovre University Hospital

Completed

Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection (HIVDCVac)

HIV Infections

Denmark
Jonsson Comprehensive Cancer Center

Completed

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Cervical Cancer | Human Papilloma Virus Infection | Cervical Intraepithelial Neoplasia Grade 3

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Baylor College of Medicine
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer

Prostate Cancer

United States
Kanuni Sultan Suleyman Training and Research Hospital

Completed

Treatment of Angiotensin Peptide (1-7) for COVID-19

COVID-19

Turkey

Search clinical trials for: HIV-1 Peptide Vaccine, Microparticulate Monovalent

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations